Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Aurinia Pharmaceuticals Inc.'s quarterly P/E stands at 14.8x, up 18.0% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 5.9% YoY to 11.2x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 7.95 | 14.83 | 2.61 | 12.01 | 14.12 | 12.56 | 224.50 | 18.60 | 142.75 | — | — | — | — |
| — | +18.0% | -98.8% | -35.4% | -90.1% | — | — | — | — | — | — | — | — | |
| P/S Ratio | 7.48 | 6.57 | 7.17 | 5.11 | 4.33 | 4.47 | 5.54 | 3.94 | 3.60 | 3.59 | 7.16 | 5.09 | 8.33 |
| — | +46.9% | +29.5% | +29.9% | +20.4% | +24.7% | -22.6% | -22.6% | -56.8% | -68.4% | +32.5% | +6.5% | -34.1% | |
| P/B Ratio | 3.93 | 3.60 | 3.81 | 4.11 | 3.62 | 3.19 | 3.51 | 2.75 | 2.26 | 2.01 | 3.42 | 2.83 | 3.52 |
| — | +12.7% | +8.3% | +49.3% | +60.3% | +58.9% | +2.8% | -2.9% | -35.9% | -49.9% | +125.4% | +12.4% | +4.8% | |
| P/FCF | 15.63 | 15.69 | 12.43 | 8.47 | 6.87 | 217.63 | 11.03 | 15.75 | 13.09 | — | 22.65 | — | — |
| — | -92.8% | +12.7% | -46.3% | -47.5% | — | -51.3% | — | — | — | +52.1% | — | — | |
| EV / EBITDA | 18.49 | 11.19 | 14.48 | 10.89 | 12.44 | 10.56 | 103.51 | 16.80 | 65.72 | — | — | — | — |
| — | +5.9% | -86.0% | -35.2% | -81.1% | — | — | — | — | — | — | — | — | |
| EV / EBIT | 20.12 | 11.51 | 13.07 | 11.79 | 13.34 | 11.10 | 142.52 | 17.46 | 81.79 | — | — | — | — |
| — | +3.7% | -90.8% | -32.4% | -83.7% | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Aurinia Pharmaceuticals Inc.'s operating margin was 53.3% in Q1 2026, up 10.2 pp QoQ and up 18.3 pp YoY. This marks the 4th consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 41.4% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 6.2% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.5% | 91.6% | 89.0% | 88.4% | 89.8% | 86.3% | 90.7% | 91.1% | 84.4% | 84.6% | 88.0% | 87.6% | 96.2% |
| — | +6.2% | -1.9% | -2.9% | +6.4% | +2.0% | +3.1% | +4.0% | -12.3% | -14.4% | -7.5% | -8.4% | +2.0% | |
| Operating Margin | 37.1% | 53.3% | 43.1% | 40.5% | 28.7% | 35.0% | -2.8% | 17.3% | -2.6% | -21.3% | -65.8% | -29.8% | -39.0% |
| — | +52.4% | +1646.2% | +133.6% | +1184.4% | +264.5% | +95.8% | +158.1% | +93.2% | +75.3% | +33.4% | -75.2% | +69.5% | |
| Net Margin | 101.5% | 44.2% | 273.4% | 42.9% | 30.7% | 37.4% | 2.4% | 21.2% | 1.3% | -21.4% | -59.6% | -24.7% | -27.7% |
| — | +18.3% | +11351.8% | +102.8% | +2334.2% | +274.9% | +104.0% | +185.8% | +104.6% | +71.9% | +34.9% | -53.1% | +78.0% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 59.9% | 6.0% | 44.5% | 9.0% | 6.3% | 6.4% | 0.4% | 3.8% | 0.2% | -2.9% | -7.0% | -3.4% | -2.9% |
| — | -6.8% | +11821.1% | +136.0% | +3047.8% | +320.1% | +105.3% | +211.2% | +106.8% | +55.7% | -11.1% | -61.6% | +64.0% | |
| ROA | 44.1% | 4.7% | 33.0% | 6.1% | 4.3% | 4.4% | 0.3% | 2.7% | 0.1% | -2.0% | -4.9% | -2.4% | -2.3% |
| — | +5.3% | +12586.5% | +129.0% | +2977.0% | +319.1% | +105.3% | +209.8% | +106.0% | +64.5% | +10.3% | -31.5% | +68.0% | |
| ROIC | 16.6% | 5.3% | 5.3% | 6.1% | 4.2% | 4.5% | -0.3% | 2.1% | -0.3% | -2.0% | -5.1% | -2.9% | -3.4% |
| — | +19.0% | +1808.2% | +194.9% | +1564.5% | +325.2% | +94.0% | +171.8% | +91.6% | +71.9% | +18.9% | -26.0% | +62.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Aurinia Pharmaceuticals Inc.'s Debt/EBITDA ratio is 1.5x, down from 2.0x last quarter — comfortably within a safe range. The current ratio has weakened 6.5% YoY to 5.55x, tightening the short-term liquidity position. Debt/Equity has declined for 4 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.12 | 0.13 | 0.21 | 0.24 | 0.22 | 0.21 | 0.23 | 0.24 | 0.25 | 0.26 | 0.24 | 0.26 |
| — | -45.6% | -38.8% | -5.6% | +3.5% | -9.7% | -18.6% | -4.8% | -8.6% | +1112.4% | +1194.6% | +1130.0% | +1204.0% | |
| Debt / EBITDA | 0.66 | 1.48 | 1.96 | 2.26 | 3.28 | 2.92 | 24.86 | 5.28 | 25.82 | — | — | — | — |
| — | -49.1% | -92.1% | -57.2% | -87.3% | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.25 | 5.55 | 5.25 | 5.76 | 5.23 | 5.93 | 4.57 | 5.60 | 5.33 | 5.60 | 5.50 | 5.77 | 6.75 |
| — | -6.5% | +14.9% | +2.7% | -1.9% | +5.8% | -17.0% | -2.9% | -21.0% | -44.4% | -42.7% | -47.6% | -48.5% | |
| Quick Ratio | 4.76 | 5.01 | 4.76 | 5.17 | 4.63 | 5.26 | 4.17 | 5.11 | 4.82 | 5.05 | 4.99 | 5.33 | 6.21 |
| — | -4.6% | +14.3% | +1.1% | -4.0% | +4.2% | -16.5% | -4.1% | -22.3% | -45.9% | -44.9% | -48.8% | -49.7% | |
| Interest Coverage | 27.36 | 44.40 | 6.48 | — | 20.84 | 23.82 | 2.02 | 13.26 | 2.23 | -6.80 | -19.16 | -8.39 | -185.68 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AUPH stock.
Aurinia Pharmaceuticals Inc.'s current P/E is 8.0x. The average P/E over the last 4 quarters is 10.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Aurinia Pharmaceuticals Inc.'s current operating margin is 37.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Aurinia Pharmaceuticals Inc.'s business trajectory between earnings reports.